CA3078335A1 - Materials and methods for inhibiting tumor growth - Google Patents

Materials and methods for inhibiting tumor growth Download PDF

Info

Publication number
CA3078335A1
CA3078335A1 CA3078335A CA3078335A CA3078335A1 CA 3078335 A1 CA3078335 A1 CA 3078335A1 CA 3078335 A CA3078335 A CA 3078335A CA 3078335 A CA3078335 A CA 3078335A CA 3078335 A1 CA3078335 A1 CA 3078335A1
Authority
CA
Canada
Prior art keywords
cancer
composition
amino acids
combination
serine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3078335A
Other languages
English (en)
French (fr)
Inventor
Sadasivan Vidyasagar
Reshu GUPTA
Stephen GATTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Entrinsic LLC
Original Assignee
University of Florida Research Foundation Inc
Entrinsic LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc, Entrinsic LLC filed Critical University of Florida Research Foundation Inc
Publication of CA3078335A1 publication Critical patent/CA3078335A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3078335A 2017-10-02 2018-10-02 Materials and methods for inhibiting tumor growth Pending CA3078335A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566787P 2017-10-02 2017-10-02
US62/566,787 2017-10-02
PCT/US2018/054015 WO2019070750A1 (en) 2017-10-02 2018-10-02 MATERIALS AND METHODS FOR INHIBITING TUMOR GROWTH

Publications (1)

Publication Number Publication Date
CA3078335A1 true CA3078335A1 (en) 2019-04-11

Family

ID=64049688

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3078335A Pending CA3078335A1 (en) 2017-10-02 2018-10-02 Materials and methods for inhibiting tumor growth

Country Status (7)

Country Link
US (1) US12109191B2 (enExample)
EP (1) EP3691628A1 (enExample)
JP (2) JP7352901B2 (enExample)
KR (1) KR102709096B1 (enExample)
CN (2) CN118078810A (enExample)
CA (1) CA3078335A1 (enExample)
WO (1) WO2019070750A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
WO2019224428A1 (en) * 2018-05-22 2019-11-28 Seleq Oy Pharmaceutical compositions for the treatment of cancer
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
IT202000000454A1 (it) * 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
US20230201151A1 (en) * 2020-05-29 2023-06-29 University Of Florida Research Foundation, Inc. Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis
CN115192564B (zh) * 2022-05-23 2023-11-17 四川大学华西医院 一种苯丙氨酸衍生物、药物组合物及其在肿瘤治疗中的应用
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH01301619A (ja) * 1988-05-30 1989-12-05 Otsuka Pharmaceut Factory Inc 癌用アミノ酸製剤
JPH0368514A (ja) 1989-08-09 1991-03-25 Morishita Pharmaceut Co Ltd 癌用アミノ酸製剤
WO1993006934A1 (en) 1991-09-30 1993-04-15 Devtech Labs, Inc. Electrostatic separation of plastic materials
US5658895A (en) 1991-10-07 1997-08-19 Otsuka Pharmaceutical Factory, Inc. Anticancer enteral feeding composition
ATE183923T1 (de) 1991-10-07 1999-09-15 Otsuka Pharma Co Ltd Enterale zubereitungen zur krebstherapie
JP3429327B2 (ja) * 1992-07-20 2003-07-22 味の素ファルマ株式会社 癌用アミノ酸輸液剤
JPH06256184A (ja) * 1993-03-05 1994-09-13 Morishita Roussel Kk 癌患者用アミノ酸製剤
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
US20050176807A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
US20060052454A1 (en) * 2004-08-09 2006-03-09 Enrique Melendez Hevia Glycine as a diet supplement for the treatment of a wide range of health problems that result from underlying metabolic disorders
JP6000253B2 (ja) 2010-09-24 2016-09-28 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 胃腸機能を改善するための材料および方法
WO2015003021A2 (en) * 2013-07-01 2015-01-08 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
JP7063468B2 (ja) 2015-09-21 2022-05-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー がんに対する栄養処置

Also Published As

Publication number Publication date
KR102709096B1 (ko) 2024-09-23
JP7352901B2 (ja) 2023-09-29
CN118078810A (zh) 2024-05-28
CN111417391B (zh) 2024-06-18
US12109191B2 (en) 2024-10-08
US20200323820A1 (en) 2020-10-15
WO2019070750A1 (en) 2019-04-11
CN111417391A (zh) 2020-07-14
JP2023171755A (ja) 2023-12-05
KR20200060492A (ko) 2020-05-29
EP3691628A1 (en) 2020-08-12
JP2020536096A (ja) 2020-12-10

Similar Documents

Publication Publication Date Title
US12109191B2 (en) Materials and methods for inhibiting tumor growth
US11666550B2 (en) CDC7 kinase inhibitors and uses thereof
US11576884B2 (en) Amino acid compositions and uses thereof
JP2023506208A (ja) 治療のための上皮ライニングとしてのポリマーの組織触媒的成長
US10882863B2 (en) Compounds for reducing c-Myc in c-Myc overexpressing cancers background
JP2023018029A (ja) 癌の処置のための医薬組成物および方法
JP2019536783A (ja) チロシン誘導体及びそれらを含む組成物
KR20160003652A (ko) 감마―글루타밀 주기 조절 방법 및 조성물
US20210106549A1 (en) Pharmaceutical compositions and methods
CN117377492A (zh) 包含蛋白激酶抑制剂的药物组合物及其医药用途
JP2018500355A (ja) グラナチシンｂの多形体
US20230255916A1 (en) Amino acid compositions and uses thereof
RU2801811C1 (ru) Новое соединение и содержащая это соединение фармацевтическая композиция для предотвращения или лечения рака
US20220175777A1 (en) Inhibitors of Multidrug Resistance Transporter P-Glycoprotein
WO2016111957A1 (en) Chloroquinoline triazole compounds, composition and uses
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
BR122024018467A2 (pt) Formulações de aminoácido e usos das mesmas

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921